In recent years, the scientific community has made significant strides in the field of gene editing, particularly through the ...

But now, in a surprise twist, the team that earned the Nobel Prize in chemistry for developing CRISPR is asking to cancel two ...

Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following ...

Two Nobel Prize winners want to cancel their own CRISPR patents in Europe In the decade-long fight to control CRISPR, the ...

With the launch of Casgevy gaining momentum, Vertex Pharmaceuticals is adding another link to its gene-editing therapy supply ...

CRISPR Therapeutics' stock may seem boring due to slow FDA trial and rollout process, but it's a strong long-term investment.

Crispr Therapeutics 40% share in Casgevy could result in revenue annual between $1.2 billion and $2.8 billion towards the end ...

Hypothetically, if you controlled which DNA is stored in the CRISPR regions, you could manipulate the bacteria into inserting ...

CRISPR Therapeutics' first therapy is called Casgevy. It treats sickle cell disease (SCD) and beta thalassemia, both rare inherited illnesses that affect the function of a person's red blood cells. It ...

Researchers at Weill Cornell Medicine developed a CRISPR-based mouse model to track prostate cancer metastasis. By using ...

View full profile. Learn about our editorial policies. Like the human immune system, bacteria learn from past infections. CRISPR sequences—short snippets of DNA from previous viruses—guide destructive ...

Phase 1/2 clinical study will evaluate the safety and preliminary efficacy of KSQ-004EX in advanced solid tumorsLEXINGTON, ...